Unknown PHASE2 INTERVENTIONAL 2-arm NCT00996684

Study of Intravitreal Microplasmin in Relieving Vitreo-Macular Adhesion in Neovascular Age-related Macular Degeneration (AMD)

Resolution of Vitreomacular Adhesion (VMA) Associated With Neovascular Age Related Macular Degeneration (AMD) With Intravitreal Microplasmin

Sponsor: ThromboGenics

Conditions Macular Degeneration

Interventions Microplasmin Placebo control

Updated 6 times since 2017 Last updated: Sep 26, 2011 Started: Oct 31, 2009 Primary completion: Sep 30, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Macular Degeneration and is currently ongoing. ThromboGenics leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ThromboGenics
University of California, Los Angeles

Data source: University of California, Los Angeles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States